- Home
- NMG vs CADL Comparison
NMG vs CADL Comparison
Compare NMG & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- CADL
- Stock Information
- Founded
- NMG 2011
- CADL 1999
- Country
- NMG Canada
- CADL United States
- Employees
- NMG N/A
- CADL N/A
- Industry
- NMG Other Metals and Minerals
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- NMG Basic Materials
- CADL Health Care
- Exchange
- NMG Nasdaq
- CADL Nasdaq
- Market Cap
- NMG 251.2M
- CADL 252.0M
- IPO Year
- NMG 2017
- CADL 2021
- Fundamental
- Price
- NMG $1.62
- CADL $5.12
- Analyst Decision
- NMG Strong Buy
- CADL Strong Buy
- Analyst Count
- NMG 2
- CADL 5
- Target Price
- NMG $2.58
- CADL $21.40
- AVG Volume (30 Days)
- NMG 37.8K
- CADL 923.9K
- Earning Date
- NMG 08-13-2025
- CADL 08-12-2025
- Dividend Yield
- NMG N/A
- CADL N/A
- EPS Growth
- NMG N/A
- CADL N/A
- EPS
- NMG N/A
- CADL N/A
- Revenue
- NMG N/A
- CADL N/A
- Revenue This Year
- NMG N/A
- CADL N/A
- Revenue Next Year
- NMG N/A
- CADL N/A
- P/E Ratio
- NMG N/A
- CADL N/A
- Revenue Growth
- NMG N/A
- CADL N/A
- 52 Week Low
- NMG $1.22
- CADL $3.79
- 52 Week High
- NMG $2.58
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- NMG 43.94
- CADL 48.58
- Support Level
- NMG $1.60
- CADL $4.73
- Resistance Level
- NMG $1.89
- CADL $5.24
- Average True Range (ATR)
- NMG 0.06
- CADL 0.29
- MACD
- NMG -0.01
- CADL 0.00
- Stochastic Oscillator
- NMG 28.57
- CADL 64.92
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.